End-to-End Program

  • End-to-End Program
  • Medhealth Outlook - Altasciences: 30 Years of Innovation in Translational Science and Clinical Success

    CNS Drug Development Solutions, Simplified.

    Altasciences CRO experts Chad Rathlef and Lisa Sanford

    Current and future development of glucagon-like peptide-1 receptor agonists (GLP-1 RAs), or simply GLP-1s, involves complexities not only in formulation but in all areas of early-phase drug development. Developing and refining preclinical models for early efficacy signals, developing and validating the bioanalytical assays necessary for quantitation, and designing the clinical studies that deliver the most robust data in this innovative therapeutic area are all key elements of a drug development program.

    In Issue 42 of The Altascientist, we review the requirements for successful GLP-1 drug development, including:

    • preclinical approaches
    • early-phase clinical study design
    • bioanalytical techniques
    • manufacturing

    Two case studies are also included. 

     

     

    Early-phase drug development is an ever-changing landscape, as emerging science leads to new promising areas of research for the treatment of human health issues. In this blog article, we review some of these areas of investigation where Altasciences has robust expertise and solution offerings.

     

    Altasciences is leading the conversation on change in the drug development industry as part of a new documentary series for the 2024 Global Health Summit, hosted alongside the WHO’s 77th World Health Assembly in Geneva in May. The mini documentary explores transformation in the slow-to-change drug development industry.

    Ophthalmic End-to-End Drug Development Solutions

    Altasciences' Proactive Drug Development Solution: Small Molecules

    Subscribe to End-to-End Program